The clinical study whether adult patients with asthma who could withdraw or reduce the treatment of ICSs without exacerbation of disease

The clinical study whether adult patients with asthma who could withdraw or reduce the treatment of ICSs without exacerbation of disease - The clinical study whether adult patients with asthma withdraw or reduce the treatment of ICSs

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000926

Enrollment

100

Registered

2007-12-03

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

continuing of the ICS therapy for same dose withdrawing of all ICSs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients with asthma achieve without all symptoms more than 6 months after the treatment of ICSs less than FP equivalent 200 mg

Exclusion criteria

Exclusion criteria: adult patients with asthma receive more than FP equivalent 400 mg, or with clinical symptoms less than 6 months

Design outcomes

Primary

Measure	Time frame
Clinical symptoms, lung function(FEV1, V50, V25), bronchial hyperresponsiveness, eosinophils in sputum and whole blood cells, IgE	—

Countries

Japan

Contacts

Public ContactNaomi Tsurikisawa

National Hospital Organization Sagamihara National Hospital Clinical Research Center for Allergy and Rheumatology

n-tsurikisawa@sagamihara-hosp.gr.jp042-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026